At a glance
- Originator Bioxel Pharma; PolyGene
- Class Albumins; Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes; Vascular disorder therapies
- Mechanism of Action Tubulin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in Canada (Intratumoural)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in Israel (Intratumoural)
- 01 Jun 2007 Preclinical development is ongoing